Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0376358 (prostate cancer)
 59,338 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Many studies have been carried out to develop unfailing diagnostic methods that could improve cancer detection. There are available cancer markers of relatively low sensitivity and specificity, which makes a reason why they not always let detect neoplasm at their earliest stage. There is a new protease cysteine enzyme named cancer procoagulant (CP) isolated from rabbit V2 Ca neoplasm and characterized by Gordon et al in 1975. Because of its exclusive presentation in the cancer tissues and blood serum of the patients with tumor, this neoplasm-cell-originated protein seems to be a new biochemical cancer disease marker. The elevated activity of CP was found in the cancers of pancreatic, breast, lung, alimentary and urinary system. The blood serum CP activity levels in the patients with renal, bladder, and prostate cancers were determined statistically higher as compared to controls but the difference varied depending on the mentioned organ of the urinary system. The CP highest activity levels was determined in the patients with prostate cancer, lower ones in bladder carcinoma ones and the lowest ones in individuals with renal tumours. That is why it appears to be justifiable to apply the determination of the CP in the oncological diagnosis in the urinary system.
 ...
PMID:[Assessment of the efficacy of cancer procoagulant (CP) activity evaluation in the oncological diagnosis of the urinary system]. 1637 35

Prostate cancer is the most prevalent malignancy in men and the third leading cause of cancer deaths worldwide. Disorders of hemostasis are commonplace in patients with prostate cancer and include disseminated intravascular coagulation, venous thromboembolism, acute coronary syndrome, and postsurgical bleeding. These hemostatic disorders contribute to the mortality and morbidity of prostate cancer. The leading mechanisms proposed to underlie prostate cancer-related coagulopathies are thought to be a hyperexpression of tissue factor, cancer procoagulant, and platelet-activating factor, which is then accompanied by release of large amounts of both prothrombotic and profibrinolytic substances into the bloodstream. Given the generally accepted notion that prostate-specific antigen (PSA) represents an important biomarker in prostate cancer diagnostics, large population screenings were initiated for early detection of cancer. However, recent clinical and economic drawbacks have been recently raised, including evidence that screening exposes patients to a significant risk of both overdiagnosis and overtreatment. Nevertheless, several lines of evidence suggest that PSA may have tumor-suppressing activities. Despite being a member of the vast kallikrein family, which actively interplays with the coagulation cascade, the role of PSA in the pathogenesis of hemostatic disorders observed in prostate cancer patients remains circumstantial and speculative. However, observations that the levels of this cancer marker tend to correlate positively with those of several markers of thrombin generation, and with postsurgical bleeding as well as with coronary atherosclerosis and negative outcomes of myocardial infarction, raise a new and intriguing scenario regarding the pathophysiological role of this serine protease.
 ...
PMID:Prostate-specific antigen, prostate cancer, and disorders of hemostasis. 2001 32